Skip to main content
. Author manuscript; available in PMC: 2014 Sep 16.
Published in final edited form as: Circ Res. 2012 Jul 25;111(8):991–1001. doi: 10.1161/CIRCRESAHA.112.268110

Figure 6. Obese VE-Cad/RTEF-1 o/e mice show restored glucose tolerance and circulating IGFBP-1.

Figure 6

A. Blood glucose levels were obtained from food-deprived (overnight), restrained, unanesthetized mice. Blood was obtained via submandibular bleed, and glucose was quantified using a CVS TRUEtrack glucose monitor on WT and VE-Cad/RTEF-1 mice fed a high fat diet. Blood glucose was significantly lower in the transgenic mice that overexpressed RTEF-1 in the endothelium (* = p≤0.05; n = 18 mice). B. Serum IGFBP-I concentration was measured by ELISA. IGFBP-1 concentration was measured with a maximum absorbance of 450 nm. The limit of sensitivity is at or above 31.2 pg/ml. (n = 3; * = p≤0.05). The IGFBP-1 levels inversely correlated with the blood glucose levels in these mice. C. Serum insulin concentration was measured by ELISA with a maxiumum absorbance of 450 nm. The limit of sensitivity is at or above 0.121 ng/ml. E. Glucose tolerance in WT and VE-Cad/RTEF-1; glucose was measured before, and, 30, 60, and 120 min after IP glucose injection. F. Insulin tolerance in WT and VECad/RTEF-1 mice at 15 weeks of HFD; glucose was measured before, and, 30, 60, and 120 min after IP insulin injection. Data are presented as mean ± S.D. (n = 7–9 animals per group). *, p≤0.05 and **, p≤ 0.01 for VE-Cad/RTEF-1 vs. WT.